Omeprazole Aurobindo

Omeprazole, the active ingredient in Omeprazole Aurobindo, is a proton pump inhibitor presented as a tablet for oral use. It reduces gastric acid secretion and is employed in the treatment of acid‑related conditions such as gastro‑oesophageal reflux disease and peptic ulcers.

GNH USA supplies Omeprazole Aurobindo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable sourcing for regulated markets, including EU and other major jurisdictions globally.

Omeprazole acts on the gastric proton pump to control acid secretion, making it useful for several acid‑related disorders.

- Gastro‑oesophageal reflux disease (GERD): reduces reflux symptoms and promotes healing of esophageal irritation. - Peptic ulcer disease: facilitates ulcer healing by lowering gastric acidity. - Erosive oesophagitis: accelerates mucosal repair in acid‑induced esophageal damage. - Helicobacter pylori eradication (as part of combination therapy): enhances the effectiveness of antibiotics. - Zollinger‑Ellison syndrome: controls excessive gastric acid production in this rare endocrine disorder.

Omeprazole is generally well tolerated, but a range of adverse reactions have been reported.

Common Side Effects: - Headache: mild to moderate intensity, often transient. - Diarrhea: loose stools that may resolve with continued therapy. - Abdominal pain: discomfort or cramping in the stomach region. - Nausea: feeling of unease or urge to vomit. - Flatulence: increased intestinal gas. - Constipation: reduced bowel movements.

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis): rash, swelling, difficulty breathing. - Clostridioides difficile infection: severe diarrhea with possible colitis. - Hypomagnesemia: low serum magnesium leading to muscle cramps or arrhythmia. - Elevated liver enzymes: potential hepatic injury. - Stevens‑Johnson syndrome: serious skin and mucous membrane disorder. - Interstitial nephritis: inflammation of kidney interstitium.

Before initiating therapy, consider the following safety measures.

- Renal function assessment: adjust use in patients with severe impairment. - Elderly patients: monitor for increased sensitivity to side effects. - Long‑term use: evaluate necessity periodically to avoid unnecessary exposure. - Magnesium monitoring: check levels during prolonged treatment. - Concomitant medications: review for drugs that may require dose adjustment. - Store below 25°C: keep in the original pack, protect from moisture.

Omeprazole can affect the pharmacokinetics of several co‑administered medicines.

Major Interactions (Avoid): - Atazanavir (HIV protease inhibitor): markedly reduced absorption. - Nelfinavir (HIV protease inhibitor): decreased plasma concentrations. - Dasatinib (cancer therapy): reduced efficacy due to altered gastric pH.

Moderate Interactions (Monitor Closely): - Clopidogrel: reduced antiplatelet effect. - Warfarin: potential increase in INR. - Digoxin: possible rise in serum levels. - Methotrexate (high dose): decreased renal clearance. - Phenytoin: altered metabolism leading to variable levels.